NL-OMON38511CompletedNot Applicable
A RANDOMIZED, SINGLE-CENTER, OPEN-LABEL, 5-WAY CROSSOVER, SINGLE-DOSE BIOAVAILABILITY/BIOEQUIVALENCE COMPARISON OF BRIVARACETAM ORAL TABLETS (10MG, 50MG, 75MG, AND 100MG) AND BRIVARACETAM INTRAVENOUS BOLUS INJECTION (100MG) IN HEALTHY VOLUNTEERS - Brivaracetam BA/BE study
CB Pharma0 sites25 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 25
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Healthy males and females
- •18-55 years, incl.
- •BMI 18.0-30.0 kg/m2 incl.
Exclusion Criteria
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
Investigators
Similar Trials
Completed
Not Applicable
A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, 3-WAY CROSSOVER STUDY TO COMPARE THE RATE AND EXTENT OF RIVASTIGMINE ABSORPTION FROM A 7 DAY RIVASTIGMINE TRANSDERMAL SYSTEM (7-DAY RTS) WITH AND WITHOUT OVERLAY WITH 24-HR EXELON® PATCH APPLIED DAILY FOR 7 DAYS IN HEALTHY MALE AND FEMALE SUBJECTS10012272dementiaNL-OMON38506oven Pharmaceuticals, Inc.18
Completed
Phase 1
A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, 3-WAY CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF BRIVARACETAM INTRAVENOUS FORMULATION GIVEN AS A 2-MINUTE IV BOLUS INJECTION, A 15-MINUTE IV INFUSION, AND AN ORALLY-DOSED TABLET IN HEALTHY MALE JAPANESE SUBJECTSJPRN-jRCT2080223863CB Japan Co., Ltd.24
Completed
Not Applicable
SINGLE CENTER, OPEN LABEL, RANDOMIZED TWO-WAY CROSSOVER STUDY OF THE EFFECT OF LACOSAMIDE 200MG TWICE DAILY ON THE SINGLE-DOSE PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN (25 MG) IN HEALTHY MALE VOLUNTEERSseizures (attacks)10039911EpilepsyNL-OMON37817CB Pharma16
Completed
Phase 3
A Single Centre, Randomized, Open Label, Single Arm, Non-Comparative, Phase III Clinical study to Evaluate the Efficacy, Safety and Tolerability of JODOACT Cream in patients with acute musculoskeletal pain.CTRI/2023/05/052581PUNARJAN AYURVEDA PRIVATE LIMITED60
Not yet recruiting
Phase 4
Investigating the effect and safety of NEERI KFT on impaired kidney functions and as an adjuvant with Nephrotoxic drugsCTRI/2023/07/054728Aimil Pharmaceuticals (India) Ltd.